Overview

Detailed Summary

Indoco Remedies Limited is a Mumbai-based pharmaceutical company engaged in manufacturing and marketing pharmaceutical formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
The company has showcased strong performance in its exports division, especially in emerging markets and its subsidiaries like FPP in the U.S. and Warren Remedies, with a notable increase in OTC business.
Indoco has launched product extensions in India’s OTC market, including products like Sensodent DSP and Sensodent DPC, enhancing its presence in sensitivity protection and clean toothpaste segments.
Indoco's API segment has seen growth, with significant developments like receiving the EIR for its Patalganga site from the USFDA, indicating strong regulatory compliance and operational standards.
Despite challenges in its acute therapies segment impacting domestic sales, Indoco has achieved rank 21st in India's prescription audit, moving past major players like Pfizer.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 1,889 Cr
Volatility: Moderate Risk
P/E Ratio: -19.8
Industry P/E: 34.1
PEG Ratio: —
P/B Ratio: 2.0
52W High: 348.10
52W Low: 163.70

Sales CAGR

1Y: -8.38%
3Y: -0.47%
5Y: 6.54%
10Y: 4.69%

Profit CAGR

1Y: -180.36%
3Y: —
5Y: —
10Y: —

ROE

TTM: -10.13%
3Y: 5.29%
5Y: 8.59%
10Y: 7.88%

ROCE

TTM: 0.77%
3Y: 8.74%
5Y: 12.40%
10Y: 11.08%

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
VENUSREM		1602.25	2,142 Cr	20.83	3.23	0.00	15.49	19.85	12.04
INDOCO		205.40	1,897 Cr	-19.94	2.02	0.10	-10.13	0.77	-3.81
SAKAR		813.60	1,810 Cr	59.39	5.58	0.00	9.40	12.54	6.34
NGLFINE		2819.10	1,740 Cr	36.22	5.29	0.00	14.62	15.37	8.81
WINDLAS		834.95	1,725 Cr	25.96	2.97	0.77	11.44	14.90	7.32
HESTERBIO		1927.30	1,664 Cr	29.90	4.62	0.56	15.45	14.34	8.48
AMRUTANJAN		562.90	1,627 Cr	28.09	4.39	0.00	17.42	23.31	11.38
Median: 7 Co.	—	834.95	1,740 Cr	28.09	4.39	0.00	14.62	14.90	8.48

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	459	450	431	433	411	390	438	485	445	476
Expenses	397	401	384	392	399	391	420	442	414	426
Operating Profit	63	49	48	40	12	-0.78	18	43	32	50
OPM %	13.69	10.87	11.07	9.30	2.93	-0.20	4.00	8.88	7.08	10.45
Other Income	-5.85	22	1.03	1.56	1.84	2.02	1.63	0.23	-5.17	3.70
Interest	10	12	14	18	16	18	26	25	26	46
Depreciation	24	26	28	29	29	29	30	32	32	32
Profit Before Tax	23	33	6.97	-4.84	-31	-46	-37	-14	-31	-25
Tax %	31.24	33.20	73.89	-106.82	8.27	9.18	0.85	31.93	5.94	5.28
Net Profit	16	22	1.82	-10	-28	-41	-36	-9.21	-29	-24
EPS in Rs	1.69	2.39	0.20	-1.08	-3.08	-4.48	-3.94	-1.00	-3.19	-2.56

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	1,097	1,045	968	1,107	1,242	1,541	1,669	1,817	1,665	1,671
Expenses	918	907	892	983	1,017	1,213	1,383	1,573	1,566	1,602
Operating Profit	178	138	77	123	224	327	286	244	99	69
OPM %	16.27	13.23	7.91	11.13	18.06	21.25	17.15	13.44	5.96	4.13
Other Income	3.97	4.69	6.15	2.44	3.12	2.33	2.34	21	6.45	7.05
Interest	6.21	24	21	26	22	14	25	38	66	78
Depreciation	63	68	72	71	73	79	71	92	114	116
Profit Before Tax	91	48	-9.31	29	132	237	193	136	-74	-118
Tax %	15.26	14.95	68.82	15.59	29.51	34.57	26.22	28.57	-4.81	1.59
Net Profit	77	41	-2.90	24	93	155	142	97	-78	-116
EPS in Rs	—	—	-0.31	2.62	10.07	16.76	15.41	10.50	-8.43	-10.69
Dividend Payout %	19.14	22.37	-93.75	11.45	14.85	13.39	14.59	14.27	-2.37	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	18	18	18	18	18	18	18	18	18	18
Reserves	558	633	657	642	661	751	886	1,010	1,091	1,004
Borrowings	125	251	233	242	203	267	257	333	672	994
Other Liabilities	239	295	330	355	389	279	325	297	363	414
Total Liabilities	941	1,197	1,238	1,258	1,272	1,315	1,486	1,658	2,145	2,430
Fixed Assets	374	440	489	468	590	570	555	678	954	997
CWIP	55	91	136	185	51	68	122	114	125	321
Investments	16	0.02	0.02	0.02	0.02	0.02	0.02	2.46	8.71	1.46
Other Assets	496	666	613	605	631	677	809	864	1,057	1,111
Total Assets	941	1,197	1,238	1,258	1,272	1,315	1,486	1,658	2,145	2,430

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	112	89	123	132	123	82	174	179	157	95
Cash from Investing Activity	-111	-171	-135	-104	-56	-67	-121	-208	-433	-339
Cash from Financing Activity	-1.62	132	-39	-16	-64	-30	-44	23	280	241
Net Cash Flow	-0.11	50	-51	12	2.97	-14	8.05	-6.54	3.93	-2.76

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	58.73%	58.74%	58.74%	58.74%	58.77%	58.77%	58.81%	58.95%	58.95%	58.95%	58.95%	58.95%
FIIs	1.57%	1.59%	1.69%	1.91%	1.47%	1.70%	1.25%	1.24%	1.22%	1.25%	1.10%	0.94%
DIIs	17.93%	17.78%	19.56%	19.42%	18.68%	18.25%	18.90%	18.77%	18.98%	18.18%	18.16%	18.18%
Public	21.76%	21.88%	20.00%	19.92%	21.08%	21.28%	21.03%	21.04%	20.85%	21.62%	21.78%	21.93%
Total Shareholders	35,431	36,588	32,600	33,201	34,511	34,416	34,676	34,497	33,129	33,319	32,659	32,276

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY25

Investor Presentation

Q4 FY24

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Indoco Remedies Ltd

Indoco Remedies Ltd (INDOCO) is currently trading at 204.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Indoco Remedies Limited is a Mumbai-based pharmaceutical company engaged in manufacturing and marketing pharmaceutical formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company has showcased strong performance in its exports division, especially in emerging markets and its subsidiaries like FPP in the U.S. and Warren Remedies, with a notable increase in OTC business. Indoco has launched product extensions in India’s OTC market, including products like Sensodent DSP and Sensodent DPC, enhancing its presence in sensitivity protection and clean toothpaste segments. Indoco's API segment has seen growth, with significant developments like receiving the EIR for its Patalganga site from the USFDA, indicating strong regulatory compliance and operational standards. Despite challenges in its acute therapies segment impacting domestic sales, Indoco has achieved rank 21st in India's prescription audit, moving past major players like Pfizer.

Over the past 52 weeks, Indoco Remedies Ltd has traded between a low of ₹163.70 and a high of ₹348.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Indoco Remedies Ltd has a market capitalization of approximately 1,897.30. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Indoco Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -19.94 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,897.30 Cr, Indoco Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Indoco Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Indoco Remedies Ltd is -19.94. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Bata India shares fell about 3% after the company reported a sharp decline in Q4 earnings, with consolidated profit down 95.2% year-on-year to Rs 2.2 crore.

Indoco Remedies said its Baddi Unit-I facility for solid oral dosage forms received EU GMP certification from the Malta Medicines Authority.

Indoco Remedies is expected to announce its Q4 FY26 results in May 2026 for the quarter ended March 31, 2026, subject to the board meeting schedule.

A Form 483 is issued by USFDA investigators at the conclusion of an inspection to notify a company of objectionable conditions that may be in violation of the Food, Drug, and Cosmetic (FD&C) Act.

Indoco Remedies Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock more with professional

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Unlock more with professional

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Indoco Remedies Ltd

What is Indoco Remedies Ltd share price today?

What does Indoco Remedies Ltd do?

What is the 52-week high and low of Indoco Remedies Ltd?

What is the market capitalization of Indoco Remedies Ltd?

Should I consider investing in Indoco Remedies Ltd stock?

Is Indoco Remedies Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Indoco Remedies Ltd belong to and why does it matter?

What is the PE ratio of Indoco Remedies Ltd?

Why did Bata India shares fall on May 29, 2026?

What did Indoco Remedies receive for its Baddi Unit-I facility?

When are Indoco Remedies Q4 FY26 results expected?

What is a USFDA Form 483 observation?

Investor’s Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Technicals

Frequently Asked Questions about Indoco Remedies Ltd

What is Indoco Remedies Ltd share price today?

What does Indoco Remedies Ltd do?

What is the 52-week high and low of Indoco Remedies Ltd?

What is the market capitalization of Indoco Remedies Ltd?

Should I consider investing in Indoco Remedies Ltd stock?

Is Indoco Remedies Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Indoco Remedies Ltd belong to and why does it matter?

What is the PE ratio of Indoco Remedies Ltd?

Why did Bata India shares fall on May 29, 2026?

What did Indoco Remedies receive for its Baddi Unit-I facility?

When are Indoco Remedies Q4 FY26 results expected?

What is a USFDA Form 483 observation?

Projection

Unlock more with professional

Announcements

Peers

Price Chart Comparison

Oscillators

Bearish

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Overview

Financial Ratios

Investment Checklist